Prescription medication · NS5A/NS5B Inhibitor (HCV)
ledipasvir/sofosbuvir
Also sold as Harvoni. Harvoni treats chronic Hepatitis C virus (HCV) genotypes 1, 4, 5, or 6.
Data updated 2026-05-15
- 13,424
- FDA reports
- 22
- InteractionsSeveral interactions
- Rx
- Availability
What the data shows
ledipasvir/sofosbuvir (Harvoni) is a prescription NS5A/NS5B Inhibitor (HCV), with 13,424 FDA adverse-event reports on file, with 22 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
ledipasvir/sofosbuvir (Harvoni) is a prescription NS5A/NS5B Inhibitor (HCV). Harvoni treats chronic Hepatitis C virus (HCV) genotypes 1, 4, 5, or 6.
Harvoni is a medicine that contains ledipasvir and sofosbuvir. It is used to treat chronic hepatitis C virus (HCV) infection in adults and children 3 years and older.
Verify with FDA → · CMS NADAC pricing →
What it does
Harvoni treats chronic Hepatitis C virus (HCV) genotypes 1, 4, 5, or 6.
Common side effects
Feeling tired, Headache, Feeling weak
Key warnings
Harvoni can cause Hepatitis B to become active again if you have had it in the past.
The sections below are summarized in plain English from ledipasvir/sofosbuvir's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Harvoni contains two medicines that stop the hepatitis C virus from multiplying in your body. Ledipasvir blocks a protein called NS5A. Sofosbuvir blocks another protein called NS5B.
How to Take It
Take one Harvoni tablet once a day. You can take it with or without food. For children, the dose is based on their weight. Follow your doctor's instructions carefully.
This is a plain-language summary of ledipasvir/sofosbuvir's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.
Pregnancy & Breastfeeding
If you are pregnant or plan to become pregnant, talk to your doctor before taking Harvoni. If Harvoni is taken with ribavirin, it is unsafe during pregnancy. Talk to your doctor if you are breastfeeding or plan to breastfeed.
This is a plain-language summary of ledipasvir/sofosbuvir's FDA labeling, not individualized advice. Ask a pharmacist or prescriber about pregnancy or breastfeeding on this medication.
Missed Dose
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule.
This is a plain-language summary of ledipasvir/sofosbuvir's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.
Storage
Store Harvoni tablets or pellets below 86°F (30°C) in the original container.
Side Effects (from patient reports)
Based on 13,424 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for ledipasvir/sofosbuvir, by number of reports
- Feeling tired
Feeling tired
4,130 reports
- Headache
Headache
3,706 reports
- Nausea 1,240
Nausea
1,240 reports
- Diarrhea 913
Diarrhea
913 reports
- Hepatitis C 883
Hepatitis C
883 reports
- Trouble sleeping 835
Trouble sleeping
835 reports
- Throwing up 442
Throwing up
442 reports
- Feeling dizzy 439
Feeling dizzy
439 reports
- Missed dose of medicine 436
Missed dose of medicine
436 reports
- Liver cancer 400
Liver cancer
400 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Serious Warnings
Harvoni can cause Hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for Hepatitis B before you start Harvoni and monitor you during and after treatment.
Known Drug Interactions
atorvastatin ↑ atorvastatin Coadministration of HARVONI with atorvastatin may be associated with increased risk of myopathy, including rhabdomyolysis.
Mechanism: Harvoni can increase the amount of atorvastatin in your system, which may lead to severe muscle problems.
What to do: Your doctor should monitor you for muscle pain or consider changing your medication.
( 5.2 , 6.2 , 7.2 ) P-gp inducers (e.g., rifampin, St. P-gp inducers (e.g., rifampin, St. Antimycobacterials: rifabutin rifampin rifapentine ↓ ledipasvir ↓ sofosbuvir Coadministration of HARVONI with rifampin, rifabutin, or rifapentine is not recommended [see Warnings and Precautions (5.3) ].
Mechanism: Rifampin reduces the levels of Harvoni in your body, which can prevent the medicine from treating your infection properly.
What to do: This combination is not recommended and should be avoided.
7 DRUG INTERACTIONS Coadministration with amiodarone may result in serious symptomatic bradycardia. Use of HARVONI with amiodarone is not recommended. Antiarrhythmics: amiodarone Effect on amiodarone, ledipasvir, and sofosbuvir concentrations unknown Coadministration of amiodarone with HARVONI may result in serious symptomatic bradycardia.
Mechanism: Taking these drugs together can cause your heart rate to drop to a dangerously slow level. While the exact reason is unknown, the combination interferes with your heart's normal rhythm.
What to do: This combination is not recommended and should be avoided. If you must take both, your doctor will need to monitor your heart rate very closely.
Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin.
Mechanism: These medications can raise the levels of rosuvastatin in your blood to unsafe levels. This increases your risk of developing serious muscle problems.
What to do: You should avoid using these two medications at the same time.
Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin.
Mechanism: These medications can cause rosuvastatin to build up in your system, which increases the risk of harmful side effects.
What to do: You should avoid taking these two medications at the same time.
This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.
Common Questions
How long will I need to take Harvoni?
Can I take Harvoni if I have kidney problems?
What should I do if I experience side effects?
Can I drink alcohol while taking Harvoni?
Will Harvoni interact with other medications I am taking?
How will I know if Harvoni is working?
What if I have HIV?
Can children take Harvoni?
What tests will I need before starting Harvoni?
What do the tablets look like?
What are the common side effects of ledipasvir/sofosbuvir?
Does ledipasvir/sofosbuvir interact with other medications?
What drug class is ledipasvir/sofosbuvir?
Is ledipasvir/sofosbuvir safe during pregnancy?
Related Medications in NS5A/NS5B Inhibitor (HCV)
Other drugs grouped near ledipasvir/sofosbuvir - same-class peers and common alternatives.
acyclovir
Zovirax
Acyclovir is an antiviral medicine.
Compare with ledipasvir/sofosbuvir →
albendazole
Albenza
Albendazole is a medicine that fights parasites.
Compare with ledipasvir/sofosbuvir →
amphotericin B
Ambisome, Fungizone
Amphotericin B liposome is an antifungal medicine.
Compare with ledipasvir/sofosbuvir →
anidulafungin
Eraxis
Eraxis is an antifungal medicine.
Compare with ledipasvir/sofosbuvir →
atovaquone/proguanil
Malarone
Malarone is a drug used to prevent and treat malaria.
Compare with ledipasvir/sofosbuvir →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on ledipasvir/sofosbuvir
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for ledipasvir/sofosbuvir
The FDA label for ledipasvir/sofosbuvir (sold under brand names such as Harvoni) classifies it as a prescription-only medication in the NS5A/NS5B Inhibitor (HCV) class. Harvoni treats chronic Hepatitis C virus (HCV) genotypes 1, 4, 5, or 6. Official labeling lists 4 commonly reported side effects, including Feeling tired, Headache, Feeling weak.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 13,424 voluntary reports. The database also lists 22 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: December 26, 2024
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages